Antegren Launch Will Be “Very Aggressive,” Biogen Idec Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects marketing expenses to increase into next year to support the launch, including dissemination of two-year Phase III data after mid-2005. First Antegren patients will likely be those who have failed other therapies, CEO Mullen says
You may also be interested in...
Antegren Data Show 66% Reduction In Multiple Sclerosis Relapse Rate
Biogen Idec and Elan are confident that one-year data will differentiate Antegren within the MS market. The companies have three weeks to familiarize prescribers and payors with natalizumab ahead of its estimated FDA action date at the end of the month.
Antegren Data Show 66% Reduction In Multiple Sclerosis Relapse Rate
Biogen Idec and Elan are confident that one-year data will differentiate Antegren within the MS market. The companies have three weeks to familiarize prescribers and payors with natalizumab ahead of its estimated FDA action date at the end of the month.
Does Red Sox Victory Mean Biotech Boom?
The Boston Red Sox World Series victory will lead to a rebound in productivity in the Cambridge biotech corridor, Biogen Idec CEO Jim Mullen joked during an Oct. 27 conference call